What happened
The OECD published this ~49-page policy paper on 6 October 2026, making the case that neurodata governance is moving beyond medical ethics into mainstream data, AI and cybersecurity governance. It argues that AI-enabled systems can 'analyse neural signals and potentially infer information about cognitive states, emotions, intentions or other characteristics that may not have been explicitly disclosed by an individual' — meaning neurodata's sensitivity grows as AI inference capability advances — and that governance must therefore follow the entire neurodata lifecycle rather than stopping at collection. Based on evidence gathered from innovators across clinical, research, workplace and consumer settings, the paper recommends risk-based differentiation of neurodata types, clearer controller/processor responsibilities and treatment of inferred neurodata, stronger regulatory pathways where medical-device, data-protection and AI oversight intersect, and investment in interoperable infrastructure and standards.
Why it matters
It is an early OECD framing of an emerging AI-governance frontier — protecting data from AI-driven inference rather than disclosure — that product and data-strategy leaders should watch as neurotechnology and brain-computer interfaces move into the enterprise and consumer markets.
Action needed
Monitor for OECD guidance adoption; if your organisation handles neural/biometric data, audit whether AI-inference risk is covered by your existing data-protection and AI-governance frameworks.